Comparative Pharmacology
Head-to-head clinical analysis: AEROSEB DEX versus ARAZLO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AEROSEB DEX versus ARAZLO.
AEROSEB-DEX vs ARAZLO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
The combination product contains a corticosteroid (dexamethasone) which suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and a topical antibiotic (usually neomycin or polymyxin B) which inhibits bacterial protein synthesis or disrupts bacterial cell membranes.
ARAZLO (tazarotene) is a retinoid prodrug that is converted to its active metabolite, tazarotenic acid, which binds to retinoic acid receptors (RARs), specifically RAR-β and RAR-γ, modulating gene expression to normalize epidermal differentiation, reduce keratinocyte proliferation, and decrease inflammation.
2 puffs (100 mcg each) intranasally twice daily
Topical: Apply 0.045% gel once daily to affected areas of the face.
None Documented
None Documented
Terminal elimination half-life is 12-15 hours in adults with normal renal function; prolonged to 24-30 hours in severe renal impairment (CrCl <30 mL/min).
Terminal half-life approximately 29 hours, supporting once-weekly topical application.
Renal elimination of unchanged drug accounts for 30-40% of the dose; fecal/biliary elimination is 50-60% as metabolites. Less than 10% is excreted unchanged in feces.
Primarily fecal excretion of unchanged drug (≥90%) and biliary elimination; renal excretion accounts for <2%.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid